CXCR2 and influenza: These findings provide important insights into the optimal timing of CXCR2 antagonist treatment to attenuate neutrophil-mediated lung pathology during influenza infections, suggesting that pharmacologic treatment with a CXCR2 antagonist and an antiviral agent could significantly improve outcomes in severe and mild influenza infections [66].